

Press Release

Stockholm, Sweden, December 7, 2022

Mendus AB: Live webcast to discuss clinical results of ADVANCE II trial presented at ASH 2022

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will host a live webcast to review the Company’s most recent clinical results of the ADVANCE II trial in AML maintenance, which will be presented at the 64th Annual Meeting of the American Society for Hematology (ASH 2022) by the ADVANCE II primary investigator, Prof Dr Arjan van de Loosdrecht, on December 12th.

The live webcast will be held on December 13th, 2022 and feature a presentation by Mendus’ CEO Erik Manting, PhD and CMO Jeroen Rovers, MD PhD. A review of the clinical results will be followed by a Q&A session.

Mendus ASH 2022 Clinical Results – Webcast Details

DATE: Tuesday, December 13, 2022

TIME: 8.00 am ET/2.00pm CET

To register and access the live webcast: <https://edge.media-server.com/mmc/p/fbg3u4we>

To register for the audio conference call:

<https://register.vevent.com/register/BI1a086aa18ea8491c8dd34eb1f5d0fe59>

Following the live webcast, a replay will be available under the “Events and Webcasts” section on the Investor page of the Company’s website: <https://mendus.com/investors/events-presentations/>

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

INVESTOR RELATIONS

Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: cdavis@lifesciadvisors.com

MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu

ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <http://www.mendus.com/>